Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
March 2026
in “
American Journal of Clinical Dermatology
”
Research cited in this study
16 / 16 results
research Longitudinal Clinical Course, Treatment Outcomes, and Relapse Patterns in Alopecia Areata: A Prospective Cohort Study
Baseline severity and relapse history affect alopecia areata treatment and recurrence.
research Patient-Reported Psychosocial Burdens and Quality of Life and Work Productivity Impacts Among Patients With Clinically Distinct Alopecia Areata Severity Profiles
Alopecia areata negatively impacts quality of life and work, even with moderate hair loss.
research SALT score distribution with ritlecitinib treatment up to 24 months in alopecia areata
research Comparison of Dermatology Life Quality Index Scores in Adults and Adolescents With Alopecia Areata
Alopecia areata affects quality of life more in adolescents than adults.
research Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme
Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.
research Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata
Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
research Alopecia Areata Treatment Patterns and Satisfaction: Results of a Real-World Cross-Sectional Survey in Europe
Current treatments for severe alopecia areata are unsatisfactory, highlighting the need for better options.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2
Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials
Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.
research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States
Alopecia areata affects many in the US, impacting quality of life, with limited treatment options.
research The Alopecia Areata Investigator Global Assessment Scale: A Measure for Evaluating Clinically Meaningful Success in Clinical Trials
The AA-IGA scale reliably measures treatment success in alopecia areata by considering both clinician and patient views.
research Treatment of Alopecia Areata: An Australian Expert Consensus Statement
Alopecia areata treatment varies, with no optimal method established yet.
research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients
Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review
Alopecia areata is caused by the immune system attacking hair follicles.